The prognostic value of stroma in pancreatic cancer in patients receiving adjuvant therapy

HPB

Volumn 17, Issue 4, 2015, Pages 292-298

  Bever, Katherine M ^a,b   Sugar, Elizabeth A ^a,b,c,d   Bigelow, Elaine ^a,b   Sharma, Rajni ^a   Laheru, Daniel ^a,b   Wolfgang, Christopher L ^a,b   Jaffee, Elizabeth M ^a,b   Anders, Robert A ^a,b   De Jesus Acosta, Ana ^a,b   Zheng, Lei ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; ACTA2 PROTEIN, HUMAN; ACTIN; COLLAGEN; KERATIN; TUMOR MARKER;

ADJUVANT CHEMORADIOTHERAPY; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; DISEASE FREE SURVIVAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREATIC STELLATE CELL; PANCREATICODUODENECTOMY; RETROSPECTIVE STUDY; STROMA CELL; TISSUE PRESERVATION; CARCINOMA, PANCREATIC DUCTAL; CHEMISTRY; COMPUTER ASSISTED DIAGNOSIS; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; MORTALITY; PANCREATIC NEOPLASMS; PATHOLOGY; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; TIME; TREATMENT OUTCOME; UNITED STATES; VERY ELDERLY;

ACTINS; ADULT; AGED; AGED, 80 AND OVER; BALTIMORE; BIOMARKERS, TUMOR; CARCINOMA, PANCREATIC DUCTAL; CHEMORADIOTHERAPY, ADJUVANT; COLLAGEN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; KERATINS; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; STROMAL CELLS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84924311219     PISSN: 1365182X     EISSN: 14772574     Source Type: Journal    
DOI: 10.1111/hpb.12334     Document Type: Article

References (16)

1. Siegel R, Ma J, Zou Z, Jemal A,. (2014) Cancer statistics, 2014. CA Cancer J Clin 64: 9-29.
2. Pierantoni C, Pagliacci A, Scartozzi M, Berardi R, Bianconi M, Cascinu S,. (2008) Pancreatic cancer: progress in cancer therapy. Crit Rev Oncol Hematol 67: 27-38.
3. Farrow B, Albo D, Berger DH,. (2008) The role of the tumour microenvironment in the progression of pancreatic cancer. J Surg Res 149: 319-328.
4. Duner S, Lopatko Lindman J, Ansari D, Gundewar C, Andersson R,. (2011) Pancreatic cancer: the role of pancreatic stellate cells in tumour progression. Pancreatology 10: 673-681.
5. Neesse A, Michl P, Frese KK, Feig C, Cook N, Jacobetz MA, et al. (2010) Stromal biology and therapy in pancreatic cancer. Gut 60: 861-868.
6. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, et al. (2009) Inhibition of Hedgehog signalling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324: 1457-1461.
7. Kraman M, Bambrough PJ, Arnold JN, Roberts EW, Magiera L, Jones JO, et al. (2010) Suppression of antitumour immunity by stromal cells expressing fibroblast activation protein-α. Science 330: 827-830.
8. Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR,. (2012) Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 21: 418-429.
9. Lutz E, Yeo CJ, Lillemoe KD, Biedrzycki B, Kobrin B, Herman J, et al. (2011) A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumour vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation. Ann Surg 253: 328-335.
10. Ozdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR, et al. (2014) Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 25: 719-734.
11. Rhim AD, Oberstein PE, Thomas DH, Mirek ET, Palermo CF, Sastra SA, et al. (2014) Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell 25: 735-747.
12. Hingorani SR, Harris WP, Beck JT, Berdov BA, Wagner SA, Pshevlotsky EM, et al. (2013) A Phase Ib multicentre international study of gemcitabine combined with PEGPH20 (PEGylated recombinant human hyaluronidase) in patients with stage IV previously untreated pancreatic cancer. J Clin Oncol 31 (Suppl.): abstr 4010.
13. Gore J, Korc M,. (2014) Pancreatic cancer stroma: friend or foe. Cancer Cell 25: 711-712.
14. Silvestris N, Gnoni A, Brunetti AE, Vincenti L, Santini D, Tonini G, et al. (2014) Target therapies in pancreatic carcinoma. Curr Med Chem 21: 948-965.
15. Amakye D, Jagani Z, Dorsch M,. (2013) Unravelling the therapeutic potential of the Hedgehog pathway in cancer. Nat Med 19: 1410-1422.
16. Herman JM, Swartz MJ, Hsu CC, Winter J, Pawlik TM, Sugar E, et al. (2008) Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol 26: 3503-3510.